CCR News and Events

Potent new LDHI inhibitor disrupts tumor growth in mice

Researchers have identified a potent LDH inhibitor, which can disrupt the energy production of tumors in mice. After exposure to the LDH inhibitor, the cancers cells began to rely on a different form of energy production, which could also be disrupted by using a second drug. Combining the two drugs had a potent anti-cancer effect. Read more...

Follicular lymphoma

Clinical trial evaluates dual drug therapy for untreated follicular lymphoma

Sep 5, 2019

Follicular lymphoma (FL) is a cancer of white blood cells (B cells) that help your body fight infections. Investigators are leading a clinical trial at the NIH Clinical Center to see if a combination therapy can slow the growth of FL in patients who have not received prior treatment.  Read more...

Steve Rosenberg

Steve Rosenberg receives 2019 Edogawa NICHE Prize

Sep 4, 2019

Steve Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, has received the 2019 Edogawa NICHE Prize. Dr. Rosenberg was recognized for his pioneering work in developing effective adoptive immunotherapies and genetically modified T cells, which has heralded the birth of a new chapter in the fight against cancer. Read more...

James Kochenderfer

James Kochenderfer named finalist for 2019 FNIH Trailblazer Prize for Clinician-Scientists

Sep 4, 2019

James N. Kochenderfer, M.D., Investigator in the Surgery Branch, has been selected as a finalist for the Foundation for the National Institutes of Health (FNIH) Trailblazer Prize for Clinician-Scientists. He is nominated for developing immunotherapies that leverage chimeric antigen receptor (CAR) T cells to treat blood cancers, including lymphoma and multiple myeloma. The winner of the Trailblazer Prize will be announced October 23, 2019. Read more...

Tim Greten, M.D.

Clinical Trial Conversation: Tim Greten describes primary liver cancer clinical trial

Sep 3, 2019

Hepatocellular carcinoma (HCC) is an aggressive form of liver cancer that is very difficult to treat, and patients live an average of six to nine months after diagnosis. Tim Greten, M.D., Deputy Chief of the Thoracic and GI Malignancies Branch, is leading a new clinical trial to determine whether administering the antibiotic vancomycin in combination with the drugs nivolumab and tadalafil will lead to cancer regression in patients with liver metastasis or primary HCC. Read more...

Bill Telford

Bill Telford receives 2019 International Society for the Advancement of Cytometry Distinguished Service Award

Sep 3, 2019

Bill Telford, Ph.D., Senior Associate Scientist in the Experimental Transplantation and Immunology Branch, has received the 2019 International Society for the Advancement of Cytometry (ISAC) Distinguished Service Award. The award honors individuals who served ISAC in a major role, provided major support to ISAC and its members or made a significant contribution to the success of ISAC. Read more...

Contour maps created from glucose and lactate signals

Researchers develop a new imaging technique to measure cancer metabolism

Sep 3, 2019

CCR researchers have developed a new technique to show metabolism from MRI images by reducing the amount of noise in those images, resulting in significantly improved quality. This breakthrough enables researchers to see biochemical processes, paving the way for a deeper understanding of tumors and potentially improved diagnosis and treatment. Read more...

Jack Shern

Jack Shern featured in LocalDVM news article

Aug 28, 2019

Jack Shern M.D., Investigator in the Pediatric Oncology Branch, was recently featured in a LocalDVM news article focused on Camp Fantastic, a week-long camp for children with cancer. In the article, Dr. Shern discusses his role as medical director of the camp and medical services provided to campers. Read more...

CAR T-cell therapy

New clinical trial tests CAR T-cell therapy for multiple myeloma

Aug 26, 2019

James N. Kochenderfer, M.D., Investigator in the Surgery Branch, is leading a study of a new way to treat multiple myeloma (MM) that uses a patient’s own T cells to target MM cells. MM is a rare blood cancer that occurs in blood, tissues, bone and bone marrow. With MM, a group of plasma cells become cancerous and multiply, crowding out healthy blood cells.  Read more...

lymphoma cells

Clinical trial tests combination therapy in untreated aggressive B-cell lymphomas

Aug 22, 2019

The Lymphoid Malignancies Branch is leading a study of a combination therapy for aggressive B-cell lymphomas using a drug that interferes with the activity of an enzyme that plays a crucial role in the development of B cells and in the cellular signaling that allows cancerous cells to multiply and survive.  Read more...

Human breast tumor cells arrested in the blood vessels of zebrafish larvae

Tumor cells in transparent fish reveal physical and molecular factors that determine metastasis sites

Aug 21, 2019

CCR researchers used zebrafish to discover that particular sites colonized by migrating tumor cells are determined by both the physical architecture of tissue and the cells’ molecular compatibility with their microenvironment. Read more...

Pages